McMaster Study Reveals Mechanism of Blood Clotting After Thinner

A cross‑campus team of researchers at McMaster University has uncovered the biological mechanism that causes a subset of patients to develop life‑threatening blood clots after receiving a widely used anticoagulant. The study, published in the journal *Blood* this week, shows that the drug can trigger an immune‑mediated reaction that activates platelets and promotes clot formation in individuals with specific genetic and environmental risk factors.

The investigators identified that the anticoagulant, a low‑molecular‑weight heparin, binds to platelet‑activating factor receptors on certain white blood cells, leading to the release of pro‑thrombotic cytokines. They also found that patients carrying a particular variant of the *PF4* gene are more likely to mount this response. By screening for the gene variant and monitoring platelet‑activating factor levels, clinicians could identify high‑risk patients before treatment. The team tested a novel monoclonal antibody that blocks the receptor interaction, which in pre‑clinical trials reduced clotting events by 70% without compromising the drug’s anticoagulant effect.

These findings provide a clear path toward personalized anticoagulant therapy. If validated in larger clinical trials, the approach could allow doctors to tailor treatment plans—either by avoiding the drug in susceptible patients or by co‑administering the blocking antibody—to prevent the rare but serious complication of thrombosis.